Looking at the filing, I need to extract financial data. The filing content cuts off mid-balance sheet, but there is enough substantive disclosure content to proceed. Let me identify key figures from what's available and structure the article accordingly.

Sotera Health Company (NASDAQ:SHC) filed its Form 10-Q for the quarterly period ended September 30, 2026 with the U.S. Securities and Exchange Commission on November 3, 2026.

Key Highlights

  • Cash position: Cash and cash equivalents stood at $412,384 thousand as of September 30, 2026, up from $344,621 thousand as of December 31, 2025, according to the filing.
  • Restricted cash (short-term): Short-term restricted cash was $9 thousand as of September 30, 2026, compared with $1,835 thousand as of December 31, 2025, the filing disclosed.
  • Shares outstanding: As of October 27, 2026, the company reported 285,630,846 shares of common stock, $0.01 par value per share, outstanding.
  • Filer classification: The company indicated it is a large accelerated filer and is not a smaller reporting company or emerging growth company.
  • Legal proceedings noted: The filing identified ongoing litigation related to ethylene oxide emissions and releases from current and former sterilization facilities as a risk factor, with the possibility of additional future claims.

Sotera Health Reports Q3 2026 Balance Sheet and Risk Disclosures

Sotera Health Company, a Delaware corporation headquartered at 9100 South Hills Blvd, Suite 300, Broadview Heights, Ohio 44147, submitted its quarterly report covering the period ended September 30, 2026. The filing identifies the company's common stock as trading on The Nasdaq Stock Market LLC under the symbol SHC. The Commission File Number assigned is 001-39729.

According to the consolidated balance sheets included in the filing, cash and cash equivalents totaled $412,384 thousand as of September 30, 2026, an increase from $344,621 thousand recorded at December 31, 2025. Short-term restricted cash declined to $9 thousand from $1,835 thousand over the same period. The balance sheet figures are presented in thousands, except per share amounts, and are unaudited for the September 30, 2026 date, the filing noted.

The filing's forward-looking statements section, which the company characterized as subject to known and unknown risks and uncertainties, identified a range of risk factors. These included supply disruptions affecting ethylene oxide and Cobalt-60 availability, fluctuations in foreign currency exchange rates, evolving environmental and health regulations, cybersecurity incidents, and the company's "significant degree of leverage." The company also disclosed ongoing and potential future legal proceedings tied to ethylene oxide use and emissions at sterilization facilities. The filing stated that forward-looking statements "speak only as of the date they are made" and that the company undertakes no obligation to update them publicly except as required by law.

What Was Disclosed

Sotera Health filed a Form 10-Q for the quarter ended September 30, 2026, reporting cash of $412,384 thousand, 285,630,846 shares outstanding as of October 27, 2026, and disclosing risk factors including ethylene oxide litigation and leverage-related concerns.